(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a session on new approaches to curing bladder and kidney cancer. Dr. Brian Rini delivered a discussant ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Las Vegas, Nevada (UroToday.com) -- Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409 ...
Lesions were segmented on both PET tracers and classified as PSMA-positive/FDG-negative (PSMA+/FDG−) or ...
The 2026 SNMMI annual meeting featured a genitourinary radiotherapeutics session and a presentation by Dr. Yalda Nikanpour ...
Dr. Pepin concluded her presentation discussing a secondary analysis of the VISION trial assessing the impact of external ...
Higher baseline PET SUVmean and cycle 1 whole body tumor volume absorbed dose are associated with a more favorable PSA ...
Vidit Sharma describes a randomized trial testing whether salvage radiation to the prostate fossa can be safely deferred in patients with biochemical recurrence after radical prostatectomy who have ...
(UroToday.com) The 2026 ASCO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Elena Sevillano discussing the SASAN-SPARING trial assessing selective ...
Overall, 1,855 male patients across all disease stages, with 179 (9.6%) reported deaths and median overall survival follow-up ...
(UroToday.com) The 2026 SNMMI annual meeting featured a genitourinary diagnosis and imaging session, including a presentation by Dr. Surekha Yadav discussing longitudinal outcomes of PSMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results